Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-21, Stock:ABBV, The news for the past five days is as follows:
2019-03-14: NEWS1: Roche Receives EC Approval for Label Expansion of Hemlibra.NEWS2: Roche Receives EC Approval for Label Expansion of Hemlibra.NEWS3: 3 Dividend Aristocrats to Buy and Hold Forever.NEWS4: 3 Dividend Aristocrats to Buy and Hold Forever.NEWS5: Roche Receives EC Approval for Label Expansion of Hemlibra.NEWS6: 3 Dividend Aristocrats to Buy and Hold Forever.NEWS7: The Timely Ten- Blue Chip Buys with Value and Yield.NEWS8: Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades.
2019-03-15: NEWS1: IWV, UNH, ABBV, HON: Large Inflows Detected at ETF.NEWS2: IWV, UNH, ABBV, HON: Large Inflows Detected at ETF.
2019-03-18: NEWS1: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS2: Big Pharma Earnings Might Not Be as Good as They Look.
2019-03-19: NEWS1: Why You Should Buy ABBV Stock for Income and Value.NEWS2: Why You Should Buy ABBV Stock for Income and Value.NEWS3: Why You Should Buy ABBV Stock for Income and Value.NEWS4: FDA puts partial hold on clinical trials of AbbVie's cancer drug.NEWS5: AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma.NEWS6: AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program.NEWS7: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS8: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.
2019-03-20: NEWS1: AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA.NEWS2: AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA.NEWS3: AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA.

Answer: Rise